NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-237-2017-1-CA-04 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION CA National Stage 3080274 Pending
NCI E-237-2017-2-CA-04 T CELL RECEPTORS RECOGNIZING MUTATED P53 CA National Stage 3077024 Pending
NCI E-237-2017-1-SG-10 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION SG National Stage 11202002635R Abandoned
NCI E-237-2017-2-SG-15 T CELL RECEPTORS RECOGNIZING MUTATED P53 SG National Stage 11202002636P Pending
NCI E-237-2017-2-IN-10 T CELL RECEPTORS RECOGNIZING MUTATED P53 IN National Stage 202047013911 Pending
NCI E-237-2017-2-BR-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 BR National Stage BR112020006012-7 Pending
NCATS E-018-2016-0-US-15 Antifungal Compound Process US DIV 16/132,973 Abandoned
NCI E-205-2018-0-US-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES US 62/732,263 Abandoned
NCI E-013-2018-0-CN-06 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development CN National Stage 201880074006.X Issued
NCI E-013-2018-0-EP-07 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development EP National Stage 18856142.7 Issued
NCI E-013-2018-0-US-03 Compositions and Methods For Treating Cancer With Anti-CD19 Immunotherapy US ORD 16/132,064 10501539 Issued PDF
NCI E-013-2018-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19 IMMUNOTHERAPY PCT PCT PCT/US2018/051167 Expired
NCI E-013-2018-0-CA-05 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development CA National Stage 3075915 Pending
NCI E-205-2016-0-US-05 NANOPARTICLE TO TARGET CANCER US National Stage 16/084,942 11246881 Issued PDF
NIAID E-118-2016-0-AU-03 Live Attenuated Zika Virus Vaccine AU National Stage 2017230112 Abandoned
NIAID E-118-2016-0-NZ-13 Live Attenuated Zika Virus Vaccine NZ National Stage 746349 Abandoned
NIA E-013-2010-0-US-15 THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS US CON 16/129,470 10617654 Issued PDF
NIA E-139-2012-2-US-13 (R,R')-4'-methoxy-1-naphthylfenoterol (MNF) For The Treatment Of Glioblastomas And Hepatocellular Carcinomas US CON 16/129,569 10485771 Issued PDF
NCI E-078-2016-0-EP-04 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF EP National Stage 17706653.7 Abandoned
NIDA E-053-2016-1-US-04 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders US National Stage 16/084,093 11299476 Issued PDF
NIDA E-053-2016-1-EP-03 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP National Stage 17711971.6 Issued
NIDA E-053-2016-1-GB-16 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders GB EP 17711971.6 Issued
NIDA E-053-2016-1-NL-22 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders NL EP 17711971.6 Issued
NIDA E-053-2016-1-RO-26 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders RO EP 17711971.6 Issued
NIDA E-053-2016-1-PT-25 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PT EP 17711971.6 Issued
NIDA E-053-2016-1-PL-24 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PL EP 17711971.6 Issued
NIDA E-053-2016-1-SK-30 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SK EP 17711971.6 Issued
NIDA E-053-2016-1-NO-23 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders NO EP 17711971.6 Issued
NIDA E-053-2016-1-RS-27 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders RS EP 17711971.6 Issued
NIDA E-053-2016-1-SI-29 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SI EP 17711971.6 Issued
NIDA E-053-2016-1-BE-08 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders BE EP 17711971.6 Issued
NIDA E-053-2016-1-AT-07 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders AT EP 17711971.6 Issued
NIDA E-053-2016-1-GR-17 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders GR EP 17711971.6 Issued
NIDA E-053-2016-1-HU-19 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders HU EP 17711971.6 Issued
NIDA E-053-2016-1-IE-20 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders IE EP 17711971.6 Issued
NIDA E-053-2016-1-DE-11 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders DE EP 17711971.6 Issued
NIDA E-053-2016-1-CZ-10 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders CZ EP 17711971.6 Issued
NIDA E-053-2016-1-HR-18 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders HR EP 17711971.6 Issued
NIDA E-053-2016-1-IT-21 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders IT EP 17711971.6 Issued
NIDA E-053-2016-1-TR-31 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders TR EP 17711971.6 Issued
NIDA E-053-2016-1-ES-13 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders ES EP 17711971.6 Issued
NIDA E-053-2016-1-SE-28 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SE EP 17711971.6 Issued
NIDA E-053-2016-1-CH-09 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders CH EP 17711971.6 Issued
NIDA E-053-2016-1-FR-15 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders FR EP 17711971.6 Issued
NIDA E-053-2016-1-DK-12 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders DK EP 17711971.6 Issued
NIDA E-053-2016-1-FI-14 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders FI EP 17711971.6 Issued
NIAID E-118-2016-0-BR-04 Live Attenuated Zika Virus Vaccine BR National Stage 1120180683426 Abandoned
NIDA E-053-2016-2-US-01 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF US 62/729,709 Abandoned
NCI E-016-2019-0-US-01 Methods Of Decreasing Influenza-induced Lethality Using Gastrin Releasing Peptide (GRP) Or Gastrin Releasing Peptide Receptor (GRPR) Antagonists US 62/729,662 Abandoned
NIAID E-118-2016-0-US-14 LIVE ATTENUATED ZIKA VIRUS VACCINE US National Stage 16/083,652 Abandoned